NCT03036098 2026-03-06CheckMate901Bristol-Myers SquibbPhase 3 Active not recruiting1,314 enrolled 23 charts 2 FDA
NCT02486718 2026-02-05Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]Hoffmann-La RochePhase 3 Active not recruiting1,280 enrolled 24 charts 2 FDA
NCT05104866 2026-02-04A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)AstraZenecaPhase 3 Active not recruiting732 enrolled 22 charts 3 FDA
NCT03456076 2026-01-30A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerHoffmann-La RochePhase 3 Active not recruiting257 enrolled 14 charts 2 FDA
NCT03734029 2025-10-06Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Daiichi SankyoPhase 3 Active not recruiting557 enrolled 22 charts 2 FDA
NCT04223856 2025-06-13EV-302Astellas Pharma IncPhase 3 Active not recruiting886 enrolled 12 charts 2 FDA
NCT04974398 2025-04-13A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaAkesoPhase 3 Active not recruiting296 enrolled 3 FDA
NCT03425643 2024-12-03MK-3475-671Merck Sharp & Dohme LLCPhase 3 Active not recruiting797 enrolled 23 charts 2 FDA